Table of Contents Author Guidelines Submit a Manuscript
Prostate Cancer
Volume 2011, Article ID 245642, 6 pages
Research Article

The Metabolic Syndrome and Biochemical Recurrence following Radical Prostatectomy

1Karmanos Cancer Institute, Wayne State University, Detroit, MI 48201, USA
2Department of Oncology, Wayne State University, Detroit, MI 48201, USA
3Departments of Epidemiology and Environmental Health Sciences and Comprehensive Cancer Center, University of Michigan, Ann Arbor, MI 48103, USA
4Department of Biostatistics and Research Epidemiology, Henry Ford Hospital, Detroit, MI 48310, USA
5Department of Epidemiology and Biostatistics, Case Western Reserve University, Cleveland, OH 44109, USA
6Departments of Epidemiology, Columbia University Mailman School of Public Health, New York, NY 10032, USA

Received 27 January 2011; Revised 3 July 2011; Accepted 1 August 2011

Academic Editor: Ann W. Hsing

Copyright © 2011 Jennifer M. Post et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Metabolic syndrome refers to a set of conditions that increases the risk of cardiovascular disease and has been associated with an increased risk of prostate cancer, particularly among African American men. This study aimed to estimate the association of metabolic syndrome with biochemical recurrence (BCR) in a racially diverse population. Among 383 radical prostatectomy patients, 67 patients had documented biochemical recurrence. Hypertension was significantly, positively associated with the rate of BCR (hazard ratio (HR) = 2.1; 95%  CI = 1.1, 3.8). There were distinct racial differences in the prevalence of individual metabolic syndrome components; however, the observed associations with BCR did not differ appreciably by race. We conclude that hypertension may contribute to a poorer prognosis in surgically treated prostate cancer patients. Our findings suggest that targeting components of the metabolic syndrome which are potentially modifiable through lifestyle interventions may be a viable strategy to reduce risk of BCR in prostate cancer.